Early detection of cancer is proven to increase a woman’s survival rate. In a recent US study presented at SBI 2021, 16,004 screening mammograms and their prior exams were analyzed by the MammoScreen. The results concluded that by thresholding at a MammoScreen Score™ of 6 (middle point of the MammoScreen Score, which is the best compromise in term of sensitivity and specificity), 27% of the cancer cases were found one year earlier by the AI system and 21% 2 years earlier, with a minimal increase in recall rate.

Potential Benefits of an AI System in the Early Detection of Breast Cancer

MammoScreen may help you reduce recalls, resulting in a reduction of unnecessary biopsies

In a recent study presented at SBI 2021, 322 mammograms from 5 hospitals in the US and France (in which 33% were diagnosed with cancer) were recalled for suspicious calcifications, and were followed-up with a biopsy procedure. Exams were processed retrospectively with MammoScreen. Thresholding at a MammoScreen Score of 4, (below this score exams are considered “low suspicion”) no cancers were missed.

The study concluded that using MammoScreen may help negate suspicious microcalcification clusters and reduce the number of biopsy procedures without missing a cancer. The positive predictive value (PPV) value was 0,4 while the NPV was 0,98. Both the PPV and NPV of the AI system were found to be significantly superior with respect to the original diagnosis. The number of unnecessary biopsies was reduced by 25%.

Exploring the ability of an AI system to differentiate breast microcalcifications